Evenity FDA Approval History
FDA Approved: Yes (First approved April 9, 2019)
Brand name: Evenity
Generic name: romosozumab-aqqg
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Osteoporosis
Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Development timeline for Evenity
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.